Hepatitis B immunity in teenagers vaccinated as infants: An Italian 17-year follow-up study

Clinical Microbiology and Infection

Volumn 20, Issue 10, 2014, Pages O680-O686

  Spada, E ^a   Romano L ^b   Tosti, M E ^a   Zuccaro, O ^a   Paladini, S ^b   Chironna, M ^c   Coppola, R C ^d   Cuccia, M ^e   Mangione, R ^f   Marrone, F ^g   Negrone, F S ^h   Parlato, A ⁱ   Zamparo, E ^j   Zotti, C M ^k   Mele, A ^a   Zanetti, A R ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e ASP Catania   (Italy)

^f Epidemiologia e Medicina Preventiva   (Italy)

^g AUSL Cesena   (Italy)

^h ASP Azienda Sanitaria Potenza   (Italy)

ⁱ ASL Napoli 2 Nord   (Italy)

^j ARPA FVG Regional Agency for Environmental of Friuli Venezia Giulia Region   (Italy)

^k UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

Booster; Hepatitis B; Immune memory; Long term protection; Vaccination

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE;

ADOLESCENT; ADULT; ARTICLE; CONCENTRATION (PARAMETERS); FEMALE; FOLLOW UP; GEOMETRIC MEAN CONCENTRATION; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE; VACCINATION; VIRUS IMMUNITY; YOUNG ADULT; IMMUNIZATION; IMMUNOLOGY; INFANT; ITALY;

ADOLESCENT; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INFANT; ITALY; MALE;

EID: 84913613263     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12591     Document Type: Article

References (29)

1. Fitzsimons D, François G, Hall A et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005; 23: 4158-4166.
2. Van Herck K, Van Damme P. Benefits of early hepatitis B immunization programs for newborns and infants. Pediatr Infect Dis J 2008; 27: 861-869.
3. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26: 6266-6273.
4. Piazza M, Da Villa G, Picciotto L et al. Mass vaccination against hepatitis B in infants in Italy. Lancet 1988; 332: 1132.
5. Zanetti AR, Tanzi E, Romanò L, Grappasonni I. Vaccination against hepatitis B: the Italian strategy. Vaccine 1993; 11: 521-524.
6. Gruppo di lavoro ICONA. 2008. Indagine di copertura vaccinale nazionale nei bambini e negli adolescenti. Rapporti ISTISAN 09/29. Available at: http://www.iss.it/binary/publ/cont/09_29_web.pdf. Accessed 31 October 2013.
7. Mele A, Mariano A, Tosti ME et al. Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. Clin Infect Dis 2007; 44: e17-e24.
8. Mele A, Tosti ME, Mariano A et al. Acute Hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges. Clin Infect Dis 2008; 46: 868-875.
9. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000; 19: 877-885.
10. Yuen MF, Lim WL, Chan AO, Wong DK, Sum SS, Lai CL. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2004; 2: 941-945.
11. But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008; 26: 6587-6591.
12. McMahon BJ, Dentinger CM, Bruden D et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009; 200: 1390-1396.
13. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, Jacquet JM. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010; 28: 730-736.
14. Wu Q, Zhuang GH, Wang XL, Wang LR, Li N, Zhang M. Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: results of a randomized placebo-controlled trial cohort from China where endemicity is high. Vaccine 2011; 29: 2302-2307.
15. Samandari T, Fiore AE, Negus S et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007; 120: e373-e381.
16. Su FH, Cheng SH, Li CY et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007; 25: 8085-8090.
17. Bialek SR, Bower WA, Novak R et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008; 27: 881-885.
18. Lu CY, Ni YH, Chiang BL et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008; 197: 1419-1426.
19. Jan CF, Huang KC, Chien YC et al. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology 2010; 51: 1547-1554.
20. Boxall EH, Sira AJ, El-Shuhkri N, Kelly DA. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis 2004; 190: 1264-1269.
21. Duval B, Gîlca V, Boulianne N et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J 2005; 24: 213-218.
22. Zanetti AR, Mariano A, Romanò L et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366: 1379-1384.
23. Gabbuti A, Romanò L, Blanc P et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 2007; 25: 3129-3132.
24. Gilca V, De Serres G, Boulianne N et al. Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later. Vaccine 2009; 27: 6048-6053.
25. Braeckman T, Van Herck K, Jilg W, Bauer T, Van Damme P. Two decades of hepatitis B vaccination in mentally retarded patients: effectiveness, antibody persistence and duration of immune memory. Vaccine 2012; 30: 4757-4761.
26. Williams JW, Christensen CJ, McMahon BJ et al. Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers. Vaccine 2001; 19: 4081-4085.
27. Bulkow LR, Wainwright RB, McMahon BJ, Parkinson AJ. Increases in levels of antibody to hepatitis B surface antigen in an immunized population. Clin Infect Dis 1998; 26: 933-937.
28. Roznovsky L, Orsagova I, Kloudova A et al. Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection 2010; 38: 395-400.
29. Poovorawan Y, Chongsrisawat V, Theamboonlers A et al. Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers. J Infect Dis 2009; 200: 33-38.